Press Releases

All Releases

Summary Toggle Celldex Therapeutics to Host Corporate 2011 Year-End and 2012 Objectives Update Call

Celldex Therapeutics to Host Corporate 2011 Year-End and 2012 Objectives Update Call 14.6 KB

Feb 29, 2012

Call scheduled for March 7, 2012 at 8:30 a.m

Read more
Summary Toggle Celldex Therapeutics to Present at the Citi 2012 Global Health Care Conference

Celldex Therapeutics to Present at the Citi 2012 Global Health Care Conference 18 KB

Feb 24, 2012

Celldex Therapeutics to Present at the Citi 2012 Global Health Care Conference NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 24, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony S. Marucci , President and Chief Executive Officer of Celldex Therapeutics, Inc.
Read more
Summary Toggle Celldex Prices Public Offering of Common Stock

Celldex Prices Public Offering of Common Stock 18 KB

Feb 24, 2012

Celldex Prices Public Offering of Common Stock NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 24, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for
Read more
Summary Toggle Celldex Announces Public Offering of Common Stock

Celldex Announces Public Offering of Common Stock 18 KB

Feb 23, 2012

Celldex Announces Public Offering of Common Stock NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 23, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it is offering shares of its common stock in an underwritten public offering. All of the shares in the offering will be sold by Celldex.
Read more
Summary Toggle Celldex Therapeutics to Participate on Therapeutic Workshop Panel at the BIO CEO & Investor Conference

Celldex Therapeutics to Participate on Therapeutic Workshop Panel at the BIO CEO & Investor Conference 17.7 KB

Feb 9, 2012

Celldex Therapeutics to Participate on Therapeutic Workshop Panel at the BIO CEO & Investor Conference NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 9, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Thomas Davis , M.D., Senior Vice President and Chief Medical Officer of Celldex
Read more
Summary Toggle Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline 18.5 KB

Jan 18, 2012

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 18, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23,
Read more
Summary Toggle Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301 19.6 KB

Jan 17, 2012

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301 NEEDHAM, Mass. --(BUSINESS WIRE)--Jan. 17, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects.
Read more
Summary Toggle Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations

Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations 22.1 KB

Jan 4, 2012

Vaccine Targets Patients with EGFRvIII-positive Recurrent Glioblastoma

Read more

Investor Relations Contacts

Press Releases

All Releases

About us

Our Pipeline

Investor Relations Contacts

Press Releases

Search:

All Releases

About us

Our Pipeline